IL101034A - 1-Biphenylimidazole derivatives processes for the preparation thereof and pharmaceutical compositions containing the same - Google Patents

1-Biphenylimidazole derivatives processes for the preparation thereof and pharmaceutical compositions containing the same

Info

Publication number
IL101034A
IL101034A IL10103492A IL10103492A IL101034A IL 101034 A IL101034 A IL 101034A IL 10103492 A IL10103492 A IL 10103492A IL 10103492 A IL10103492 A IL 10103492A IL 101034 A IL101034 A IL 101034A
Authority
IL
Israel
Prior art keywords
group
carbon atoms
methyl
groups
alkyl
Prior art date
Application number
IL10103492A
Other languages
English (en)
Other versions
IL101034A0 (en
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27549327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL101034(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL101034A0 publication Critical patent/IL101034A0/xx
Publication of IL101034A publication Critical patent/IL101034A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
IL10103492A 1991-02-21 1992-02-21 1-Biphenylimidazole derivatives processes for the preparation thereof and pharmaceutical compositions containing the same IL101034A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2709891 1991-02-21
JP9658891 1991-04-26
JP13488991 1991-06-06
JP16713891 1991-07-08
JP17397291 1991-07-15
JP18484191 1991-07-24

Publications (2)

Publication Number Publication Date
IL101034A0 IL101034A0 (en) 1992-11-15
IL101034A true IL101034A (en) 1996-10-16

Family

ID=27549327

Family Applications (3)

Application Number Title Priority Date Filing Date
IL10103492A IL101034A (en) 1991-02-21 1992-02-21 1-Biphenylimidazole derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
IL114996A IL114996A (en) 1991-02-21 1992-02-21 1-biphenylimidazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
IL11499695A IL114996A0 (en) 1991-02-21 1995-08-18 1-Biphenylimidazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL114996A IL114996A (en) 1991-02-21 1992-02-21 1-biphenylimidazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
IL11499695A IL114996A0 (en) 1991-02-21 1995-08-18 1-Biphenylimidazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same

Country Status (22)

Country Link
EP (2) EP0545912B1 (de)
JP (1) JPH07121918B2 (de)
KR (1) KR0128289B1 (de)
CN (3) CN1045770C (de)
AT (2) ATE200778T1 (de)
CA (2) CA2229000C (de)
CZ (1) CZ289194B6 (de)
DE (6) DE122011000011I1 (de)
DK (2) DK0545912T3 (de)
ES (2) ES2157895T7 (de)
FI (2) FI112942B3 (de)
GR (2) GR3035906T3 (de)
HU (3) HU223338B1 (de)
IE (1) IE920540A1 (de)
IL (3) IL101034A (de)
IS (1) IS1756B (de)
LU (4) LU91056I2 (de)
NL (3) NL300133I2 (de)
NO (6) NO304516B3 (de)
NZ (1) NZ241681A (de)
PT (2) PT545912E (de)
RU (1) RU2128173C1 (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
EP0573218B1 (de) * 1992-06-02 2001-03-07 Sankyo Company Limited 4-Carboxyimidazolderivate als Angiotensin-II-Antagonisten und ihre therapeutische Verwendung
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
WO1995024902A1 (en) * 1994-03-16 1995-09-21 Sankyo Company, Limited Ocular tension depressant
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AUPN786896A0 (en) 1996-02-02 1996-02-29 Telstra Corporation Limited A network fault system
AU714618B2 (en) 1996-07-15 2000-01-06 Sankyo Company Limited Medicinal composition
AU5576498A (en) * 1997-02-05 1998-08-26 Sankyo Company Limited Prophylactic or therapeutic agent for diabetic complication
USD441509S1 (en) 1997-08-25 2001-05-01 Mastrad S.A. Combined hand cleaner and hand cleaner base
AU141230S (en) 1999-02-26 2000-07-25 Unilever Plc Detergent tablet
WO2000078727A1 (en) * 1999-06-22 2000-12-28 Takeda Chemical Industries, Ltd. Process for the preparation of imidazole derivatives
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4521844B2 (ja) * 2000-04-18 2010-08-11 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
PT1336407E (pt) 2000-11-21 2006-07-31 Sankyo Co Composicao contendo um antagonista do receptor de angiotensina e um diuretico e sua utilizacao para o tratamento da hipertensao
NZ531346A (en) * 2001-08-28 2005-10-28 Sankyo Co Medicinal compositions containing angiotensin II receptor antagonist
RS20050590A (sr) 2003-01-31 2007-09-21 Sankyo Company Limited, Lek za profilaksu i tretman arterioskleroze i hipertenzije
CN1197866C (zh) * 2003-03-21 2005-04-20 上海医药工业研究院 4，6－二氢呋喃并[3,4－d]咪唑－6－酮衍生物及其盐和制备方法
ES2535291T3 (es) 2003-04-15 2015-05-08 Daiichi Sankyo Company, Limited Medoxomilo de olmesartán para prevención o tratamiento de enfermedades oculares angiogénicas
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
EP1689383B1 (de) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Neue phosphor enthaltende thyromimetika
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2005206603A (ja) * 2004-01-21 2005-08-04 Teva Pharmaceutical Industries Ltd カンデサルタンシレキセチルの調製
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
NZ549535A (en) 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
CN1993355A (zh) * 2004-09-02 2007-07-04 特瓦制药工业有限公司 奥美沙坦酯的纯化方法
EP2248520A3 (de) 2004-10-08 2010-11-17 Novartis AG Verwendung von Reninhemmern zur Prävention oder Behandlung von diastolischer Dysfunktion oder diastolischer Herzinsuffizienz
KR101021828B1 (ko) 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
EP1716138A1 (de) * 2004-12-30 2006-11-02 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung von olmesartan-medoxomil bei einem ph-wert von über 2,5
CN101094850A (zh) * 2005-01-03 2007-12-26 特瓦制药工业有限公司 具有较低水平杂质的奥美沙坦酯
ES2334386T3 (es) * 2005-04-22 2010-03-09 Daiichi Sankyo Company, Limited Producto farmaceutico para la prevencion o el tratamiento de una enfermedad metabolica osea.
EP1816131A1 (de) * 2006-02-06 2007-08-08 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung von Olmesartan Medoxomil
EP1910343B1 (de) 2005-07-29 2014-10-29 Krka Verfahren zur herstellung von olmesartan-medoxomil
CZ299265B6 (cs) * 2005-10-20 2008-05-28 Zentiva, A. S. Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
CZ299902B6 (cs) * 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
EP1801111B1 (de) * 2005-12-20 2014-07-16 LEK Pharmaceuticals d.d. Polymorphe Formen von Olmesartan Medoxomil
WO2007097451A1 (ja) 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬パッケージ
EP1891952B1 (de) 2006-05-04 2011-10-05 LEK Pharmaceuticals d.d. Pharmazeutische Zusammensetzung mit Olmesartan-Medoxomil
US8048904B2 (en) * 2006-06-19 2011-11-01 Matrix Laboratories Ltd. Process for the preparation of olmesartan medoxomil
US8242151B2 (en) 2007-02-07 2012-08-14 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
EP2481408A3 (de) 2007-03-01 2013-01-09 Probiodrug AG Neue Verwendung von Inhibitoren der Glutaminyl Cyclase
EP2141160A4 (de) * 2007-03-23 2011-06-29 Daiichi Sankyo Co Ltd Zerriebener kristall von olmesartanmedoxomil
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101311169B (zh) * 2007-05-21 2011-03-16 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法
CN101311168B (zh) * 2007-05-21 2010-12-08 上海医药工业研究院 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
GB0710680D0 (en) * 2007-06-05 2007-07-11 Generics Uk Ltd Novel crystalline form of olmesartan medoxmil
EP2174666B1 (de) * 2007-06-22 2013-12-18 Daiichi Sankyo Company, Limited Medizinisches mittel zur behandlung von amyloid beta-induzierten störungen der cerebralen zirkulation oder des cerebralen blutflusses
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
KR101630885B1 (ko) * 2008-06-09 2016-06-15 다이이찌 산쿄 가부시키가이샤 1-비페닐메틸이미다졸 화합물의 제조 방법
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8486980B2 (en) 2008-08-06 2013-07-16 Kyowa Hakko Kirin Co., Ltd. Tricyclic compound
EP2374799B1 (de) 2008-11-17 2013-05-22 Shanghai Institute of Pharmaceutical Industry Verfahren zur herstellung von 4-(1-hydroxy-1-methylethyl)-2-propylimidazol-5-carboxylaten
JP2009102340A (ja) * 2008-12-04 2009-05-14 Daiichi Sankyo Co Ltd イミダゾール誘導体の製造法（２）
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
NZ596326A (en) 2009-04-28 2014-02-28 Daiichi Sankyo Co Ltd Novel solvate crystals
ES2527686T3 (es) 2009-04-28 2015-01-28 Daiichi Sankyo Company, Limited Procedimiento de producción de olmesartán medoxomil
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
CN102050816A (zh) * 2009-10-28 2011-05-11 北京万全阳光医学技术有限公司 一种合成奥美沙坦酯的方法
HUP0900788A2 (en) 2009-12-16 2011-11-28 Sanofi Aventis Process for producing 4-bromomethyl-biphenyl derivatives
EP2521540A2 (de) 2010-01-05 2012-11-14 Ratiopharm GmbH Feste orale darreichungsform mit einem olmesartan-medoxomil
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
JP5137996B2 (ja) * 2010-04-28 2013-02-06 日本曹達株式会社 ４，５−ジシアノイミダゾールの製造方法
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
EP2425859A1 (de) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulationen von Olmesartan
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102206208A (zh) * 2010-12-24 2011-10-05 上海现代制药股份有限公司 含低水平杂质的奥美沙坦酯的制备方法
CN102060778B (zh) * 2010-12-24 2012-05-23 江苏江神药物化学有限公司 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
CN103874697A (zh) 2011-08-03 2014-06-18 协和发酵麒麟株式会社 二苯并氧杂*衍生物
AP2014007766A0 (en) 2011-12-15 2014-07-31 Takeda Pharmaceuticals Usa Inc Combination os azilsartan and chlorthlidone for treating hypertension black patients
CN103304550B (zh) * 2012-03-16 2016-01-27 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
JP5925899B2 (ja) 2012-08-31 2016-05-25 株式会社エーピーアイ コーポレーション ビアリール化合物の製造方法
JP5881837B2 (ja) 2012-09-26 2016-03-09 株式会社エーピーアイ コーポレーション テトラゾール化合物の脱保護方法
WO2014054798A1 (ja) 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CN103012382B (zh) * 2012-12-05 2016-10-05 迪沙药业集团有限公司 一种奥美沙坦酯的制备方法
CN103044407A (zh) * 2012-12-20 2013-04-17 安徽悦康凯悦制药有限公司 奥美沙坦酯的制备方法
CN103965167A (zh) * 2013-01-29 2014-08-06 通化济达医药有限公司 咪唑羧酸衍生物
JP2014152127A (ja) * 2013-02-06 2014-08-25 Tokuyama Corp オルメサルタンメドキソミルの製造方法
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
EP3025711B1 (de) 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medikament zur vorbeugung oder behandlung von hypertonie
CN103880825B (zh) * 2014-03-14 2019-03-05 浙江华海药业股份有限公司 一种高纯的三苯甲基奥美沙坦酯的制备工艺
CN104356069B (zh) * 2014-11-18 2016-09-14 黄冈鲁班药业有限公司 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用
CN104447564B (zh) * 2014-11-24 2016-08-31 广州天赐高新材料股份有限公司 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法
CN104402873A (zh) * 2014-12-02 2015-03-11 千辉药业（安徽）有限责任公司 一种奥美沙坦酯中间体的制备方法
CN105481842A (zh) * 2015-12-15 2016-04-13 江苏中邦制药有限公司 一种奥美沙坦酯的制备方法
EP3434284A4 (de) 2016-03-24 2019-11-13 Daiichi Sankyo Company, Limited Medizin zur behandlung von nierenerkrankung
CN106749195A (zh) * 2016-12-30 2017-05-31 青岛黄海制药有限责任公司 一种奥美沙坦酯中间体杂质合成、鉴定的方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN109081812B (zh) * 2018-08-30 2022-08-16 黄冈鲁班药业股份有限公司 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物
KR102131359B1 (ko) 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
CN112778209B (zh) * 2019-11-04 2024-05-14 宜昌东阳光长江药业股份有限公司 一种二酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4916129A (en) 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
EP0400835A1 (de) 1989-05-15 1990-12-05 Merck & Co. Inc. Substituierte Benzimidazole als Angiotensin II-Hemmer
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
JPH05504359A (ja) * 1990-02-13 1993-07-08 メルク・エンド・カムパニー・インコーポレーテツド 置換ベンジル部分を含むイミダゾールアンギオテンシン２拮抗物質
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Also Published As

Publication number Publication date
NL300133I2 (nl) 2004-03-01
DE69231798T3 (de) 2012-07-12
LU91571I2 (fr) 2009-07-13
EP0503785A1 (de) 1992-09-16
ES2157895T3 (es) 2001-09-01
NL300375I1 (nl) 2009-04-01
CN1121859C (zh) 2003-09-24
CN1045770C (zh) 1999-10-20
CN1188645A (zh) 1998-07-29
ATE200778T1 (de) 2001-05-15
HU211934A9 (en) 1996-01-29
NO954507D0 (no) 1995-11-09
CZ289194B6 (cs) 2001-11-14
JPH0578328A (ja) 1993-03-30
CN1101384C (zh) 2003-02-12
GR3035909T3 (en) 2001-08-31
FI112942B (fi) 2004-02-13
HK1011361A1 (en) 1999-07-09
CN1065063A (zh) 1992-10-07
LU91847I2 (fr) 2011-09-26
NO2003009I2 (en) 2007-12-11
FI920749A0 (fi) 1992-02-20
ES2157895T7 (es) 2012-06-14
ES2156866T3 (es) 2001-08-01
DE10299043I1 (de) 2003-03-27
DE10299043I2 (de) 2003-08-07
NO304516B1 (no) 1999-01-04
IE970752A1 (en) 2000-02-23
DE122005000051I1 (de) 2006-01-26
NZ241681A (en) 1993-07-27
HU9601179D0 (en) 1996-07-29
EP0503785B3 (de) 2012-02-29
DE122009000024I1 (de) 2009-09-17
FI112942B3 (fi) 2012-03-13
EP0503785B1 (de) 2001-04-25
JPH07121918B2 (ja) 1995-12-25
LU91056I2 (fr) 2004-10-19
CA2229000C (en) 2002-04-09
DK0545912T3 (da) 2001-06-18
IS3819A (is) 1992-08-22
RU2128173C1 (ru) 1999-03-27
PT545912E (pt) 2001-08-30
AU647887B2 (en) 1994-03-31
ATE200777T1 (de) 2001-05-15
NL300227I1 (nl) 2006-06-01
FI112941B (fi) 2004-02-13
DE122011000011I1 (de) 2011-06-16
HU223667B1 (hu) 2004-11-29
HUT60475A (en) 1992-09-28
FI920749A7 (fi) 1992-08-22
NO920688L (no) 1992-08-24
EP0545912B1 (de) 2001-04-25
CA2229000A1 (en) 1992-08-22
NO954507L (no) 1992-08-24
CN1189490A (zh) 1998-08-05
NL300133I1 (nl) 2003-10-01
GR3035906T3 (en) 2001-08-31
DE69231798D1 (de) 2001-05-31
NO2009019I1 (no) 2009-09-21
LU91330I2 (fr) 2007-06-04
IE920540A1 (en) 1992-08-26
HU223338B1 (hu) 2004-06-28
IL114996A0 (en) 1995-12-08
DE69231798T2 (de) 2001-12-06
CZ51692A3 (en) 1993-03-17
IL114996A (en) 1997-07-13
DK0503785T3 (da) 2001-06-18
NO2006012I1 (no) 2006-10-30
EP0545912A3 (de) 1993-06-16
IS1756B (is) 2000-12-28
NO304517B1 (no) 1999-01-04
CA2061607A1 (en) 1992-08-22
RU95101430A (ru) 1997-02-20
DE69231801D1 (de) 2001-05-31
NO2011013I1 (no) 2011-08-22
HU9200578D0 (en) 1992-05-28
HK1011969A1 (en) 1999-07-23
NO920688D0 (no) 1992-02-21
FI955248A0 (fi) 1995-11-02
AU1112592A (en) 1992-08-27
KR0128289B1 (ko) 1998-04-02
DE69231801T2 (de) 2001-12-06
NO304516B3 (no) 2012-06-11
EP0545912A2 (de) 1993-06-09
CA2061607C (en) 1999-01-19
PT503785E (pt) 2001-08-30
IL101034A0 (en) 1992-11-15
FI955248A7 (fi) 1995-11-02
KR920016429A (ko) 1992-09-24

Similar Documents

Publication Publication Date Title
RU2128173C1 (ru) Производные 1-бифенилметилимидазола, способ их получения и фармацевтическая композиция для лечения и профилактики гипертензии
US5616599A (en) Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IE83299B1 (en) 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use
US5459148A (en) Biphenyl derivatives and their use for the treatment of hypertension and cardiac disease
EP0573218B1 (de) 4-Carboxyimidazolderivate als Angiotensin-II-Antagonisten und ihre therapeutische Verwendung
JPH06211736A (ja) 置換シクロヘキサン誘導体、それらの製造方法および疾患治療のための化合物の使用
RU2092481C1 (ru) Производные 1-бифенилметилимидазола, их фармацевтически приемлемые соли или эфиры и способ их получения
HK1011969B (en) 1-biphenylimidazole derivatives, their preparation and their therapeutic use
IE83343B1 (en) 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use
HK1011361B (en) 1-biphenylmethylimidazole derivatives, their preparation and their therapeutic use
CZ289244B6 (cs) 1-Bifenylmethylimidazolové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired